ArticleNPJ precision oncology2021

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells.

Mikkel G Terp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.